CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch
CoronaWatch
1 other identifier
observational
50
1 country
1
Brief Summary
In December 2019, a new viral disease called COVID-19 emerged. It is caused by the new corona virus SARS-CoV-2. It was initially described in the chinese city of Wuhan. In the following months, the disease developed into a pandemic, which is currently an immense international challenge. So far, there is little scientific evidence on risk stratification, especially on the prognostic value of biomarkers (laboratory-chemical, clinical and digital) with regard to clinical deterioration of patients with COVID-19. Further scientific studies are needed to establish optimal risk stratification and early detection of clinical deterioration. In this study, the investigators aim to observe patients with COVID-19 via SmartWatches on top of their clinical routine. The investigators aim to determine, whether the addition of SmartWatches enhances risk stratification, early detection of complications and prognostics in patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 15, 2020
CompletedFirst Submitted
Initial submission to the registry
April 20, 2020
CompletedFirst Posted
Study publicly available on registry
May 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 20, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
May 20, 2022
CompletedMay 26, 2022
May 1, 2022
2.1 years
April 20, 2020
May 20, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Biomarker
Identification of biomarkers (laboratory-chemical, clinical, digital) for risk stratification, early detection of complications and prognosis
3 months
Secondary Outcomes (5)
Protective factors
3 months
SmartWatch compliance
3 months
Arrhythmias
3 months
QT time changes
3 months
Longitudinal risk models
3 months
Study Arms (1)
COVID-19
Patients with COVID-19, who have cardiovascular diseases or receive medication with arrhythmogenic risk.
Interventions
Eligibility Criteria
The study population consists of patients with COVID-19. The patients have got a cardiovascular disease or therapy with potential cardiovascular complications.
You may qualify if:
- Diagnosis of COVID-19 (detection by PCR)
- Age ≥ 18
- The patient has understood the study design and the informed consent form and has signed and dated the informed consent form
- The patient has got a cardiovascular disease or therapy with potential cardiovascular complications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Heidelberglead
- The German Heart Foundationcollaborator
- Klaus Tschira Stiftung, Germanycollaborator
- Freunde und Förderer der Kardiologie Heidelberg; Germanycollaborator
Study Sites (1)
Department III of Internal Medicine, University Hospital Heidelberg
Heidelberg, Baden-Wurttemberg, 69115, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamin Meder, Prof. Dr.
University Hospital Heidelberg
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. med.
Study Record Dates
First Submitted
April 20, 2020
First Posted
May 6, 2020
Study Start
April 15, 2020
Primary Completion
May 20, 2022
Study Completion
May 20, 2022
Last Updated
May 26, 2022
Record last verified: 2022-05